Adalvo Acquires Enzene's Romiplostim Biosimilar Program
The deal transfers a biosimilar candidate referencing Amgen's NPLATE, a treatment for immune thrombocytopenia, to Adalvo.
Updated on Nov. 6, 2026 in Biotech
Adalvo has acquired Enzene's romiplostim biosimilar program, which references Amgen's NPLATE. Enzene will continue as the program's development and manufacturing partner.
Why it matters
The acquisition combines Adalvo's global development, regulatory and commercial platform with Enzene's scientific and manufacturing expertise. The arrangement positions the biosimilar candidate for regulatory filings across multiple markets.
Romiplostim is an Fc-peptide fusion protein (peptibody) and a thrombopoietin receptor agonist (TPO-RA) used to treat adult and chronic pediatric immune thrombocytopenia (ITP). Financial terms and the biosimilar's clinical comparability data were not disclosed.
The players
Adalvo
Adalvo is a global pharmaceutical company with development, regulatory and commercial capabilities that now holds the romiplostim biosimilar program.
Enzene
Enzene is a biosimilar developer and manufacturer based in India that will remain the program's development and manufacturing partner.
Amgen
Amgen is the biotechnology company that markets NPLATE, the reference product for the romiplostim biosimilar.
The details
Adalvo acquired the romiplostim program from Enzene, which will continue supplying the product from its GMP-approved facilities in Pune, India. Enzene will also provide regulatory filing support to the U.S. Food and Drug Administration, the European Medicines Agency, and other international regulators.
Timeline
October 27, 2026: Adalvo announced the acquisition of Enzene's romiplostim biosimilar program.
The Tech Race
The program references Amgen's NPLATE, the original romiplostim product, and positions Adalvo to compete in biosimilar versions of this thrombopoietin receptor agonist. The deal reflects continued biosimilar development aimed at expanding access to ITP treatments beyond the reference brand.
If approved, the biosimilar would offer an alternative to the reference romiplostim therapy for adults and children with immune thrombocytopenia. Patients and prescribers would only see practical effects after regulatory decisions are issued in each market, and no timeline has been announced.
The takeaway
Biosimilar partnerships like this one show how development, regulatory and manufacturing roles are increasingly split across companies. Readers tracking treatment costs for immune thrombocytopenia should watch for future regulatory decisions on this candidate.
Further reading
Explore more biotech developments shaping drug access and biosimilar competition worldwide.
Source note: This article includes information reported by Big Molecule Watch.
